5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid | 213382-49-1

• 物质功能分类: 生物化工 - 生化试剂
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 5,6-dihydroxy-8Z,11Z,14Z-eicosatrienoic acid
• 英文别名: (8Z,11Z,14Z)-5,6-dihydroxyicosa-8,11,14-trienoic acid
• CAS: 213382-49-1
• 化学式: C₂₀H₃₄O₄
• 分子量: 338.5
• InChiKey: GFNYAPAJUNPMGH-QNEBEIHSSA-N

物化性质

• 沸点：
  515.2±50.0 °C(Predicted)
• 密度：
  1.025±0.06 g/cm3(Predicted)
• 溶解度：
  DMF：50 mg/ml； DMSO：50 mg/ml；乙醇：50 mg/ml； PBS pH 7.2：1 mg/ml
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  4.5
• 重原子数：
  24
• 可旋转键数：
  15
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Differential diagnosis of liver disease
  申请人：The Regents of the University of California

  公开号：US10422786B2

  公开（公告）日：2019-09-24

  The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.

  本发明涉及肝脏疾病的基本无创诊断，特别是能够在早期阶段对此类疾病的进展进行干预。本发明进一步涉及使用血浆生物标志物来区分非酒精性脂肪性肝炎（NASH）与非酒精性脂肪肝（NAFL）和非酒精性脂肪肝（NAFLD）以及正常对照组。具体来说，本发明涉及利用血浆中游离二十烷酸和其他多不饱和脂肪酸（PUFA）代谢物水平来区分非酒精性脂肪性肝炎（NASH）和非酒精性脂肪性肝病（NAFL）以及非酒精性脂肪性肝病（NAFLD）正常对照组。
• Metabolomics-Based Identification of Disease-Causing Agents
  申请人：Skolnick Jeffrey

  公开号：US20110246081A1

  公开（公告）日：2011-10-06

  A method, computer-readable medium, and system for identifying one or more metabolites associated with a disease, comprising: comparing gene expression data from diseased cells to gene expression data from control cells in order to deduce genes that are differentially-regulated in the diseased cells relative to the control cells; based on enzyme function and pathway data for all human metabolites that utilize the genes that are differentially-regulated in the disease cells, identifying one or more metabolites whose intracellular levels are higher or lower in diseased cells than in control cells, and thereby associating the one or more metabolites with the disease.
• DIFFERENTIAL DIAGNOSIS OF LIVER DISEASE
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160305925A1

  公开（公告）日：2016-10-20

  The present invention relates to the substantially non-invasive diagnosis of liver disease, especially to enable intervention in the progression of such disease at an early stage. This invention further relates to the use of plasma biomarkers to differentiate nonalcoholic steatohepatitis (NASH) from nonalcoholic fatty liver (NAFL) and non-nonalcoholic fatty liver disease (NAFLD), and normal controls. Specifically, the invention relates to the use of free eicosanoids and other polyunsaturated fatty acid (PUFA) metabolite levels in plasma to differentiate NASH from NAFL and non-NAFLD normal controls.